Target Information
| Target General Infomation | Top | ||||
|---|---|---|---|---|---|
| Target ID |
T18226
|
||||
| Target Name |
HUMAN clathrin-mediated endocytosis (RME)
|
||||
| Target Status |
Target in Phase 3 Trial
|
[1] | |||
| Disease | [+] 3 Target-related Diseases | + | |||
| 1 | COVID-19 [ICD-11: 1D6Y] | ||||
| 2 | Middle East Respiratory Syndrome [ICD-11: 1D64] | ||||
| 3 | Severe acute respiratory syndrome [ICD-11: 1D65] | ||||
| Drugs and Modes of Action | Top | ||||
|---|---|---|---|---|---|
| Drugs in Phase 3 Trial | [+] 1 Drugs in Phase 3 Trial | + | |||
| 1 | Chlorpromazine | Drug Info | Phase 3 Trial | COVID-19 | [2] |
| Investigative agents | [+] 4 Investigative agents | + | |||
| 1 | Triflupromazine | Drug Info | Investigative | MERS | [3] |
| 2 | Thiethylperazine | Drug Info | Investigative | MERS | [3] |
| 3 | Fluphenazine | Drug Info | Investigative | MERS | [4] |
| 4 | Promethazine | Drug Info | Investigative | MERS | [3] |
| Mode of Action | [+] 1 Modes of Action | + | |||
| Inhibitor | [+] 5 Inhibitor drugs | + | |||
| 1 | Chlorpromazine | Drug Info | [1], [5] | ||
| 2 | Fluphenazine | Drug Info | [3], [4] | ||
| 3 | Promethazine | Drug Info | [6] | ||
| 4 | Thiethylperazine | Drug Info | [3] | ||
| 5 | Triflupromazine | Drug Info | [3] | ||
| References | Top | ||||
|---|---|---|---|---|---|
| 1 | Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic Strategy in COVID-19. Int J Biol Sci. 2020 Mar 15;16(10):1724-1731. | ||||
| 2 | ClinicalTrials.gov (NCT04366739) Repurposing of Chlorpromazine in Covid-19 Treatment. U.S. National Institutes of Health. | ||||
| 3 | Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93. | ||||
| 4 | Testing of Middle East respiratory syndrome coronavirus replication inhibitors for the ability to block viral entry. Antimicrob Agents Chemother. 2015 Jan;59(1):742-4. | ||||
| 5 | Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. | ||||
| 6 | Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020 Mar;19(3):149-150. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.